News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Centers for Disease Control and Prevention (CDC) Advisory Committee Recommends Preferential Use Of Live Attenuated Influenza Vaccine (LAIV) For Eligible Children 2 To 8 Years Of Age



6/26/2014 8:58:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WILMINGTON, Del.--(BUSINESS WIRE)--The MedImmune Specialty Care division of AstraZeneca announced that the U.S. Centers for Disease Control & Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that when available, Live Attenuated Influenza Vaccine (LAIV) should be used for healthy children 2 to 8 years of age, who have no contraindications or precautions. The ACIP’s unanimous vote was based on a systematic evidence-based assessment methodology called the Grading of Recommendations Assessment, Development and Evaluation (also known as GRADE).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Influenza
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES